Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting competing offers.

Monteverde & Associates PC is investigating four merger and acquisition transactions involving RAPT Therapeutics, Amicus Therapeutics, Tamboran Resources, and Contango Ore. The firm is encouraging shareholders to act before upcoming votes and tender offer deadlines in March 2026, citing concerns about the proposed deals.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their merger and acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger and acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures, and is offering contingent fee representation.

Law firm Brodsky & Smith has initiated investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Clearwater Analytics ($24.55/share), Katapult Holdings (6% ownership in combined entity), Janus Henderson ($49.00/share), and Amicus Therapeutics ($14.50/share).

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $4.8 billion on Friday. The acquisition is expected to accelerate revenue growth and be accretive to earnings within 12 months. Analysts view the deal favorably, with Truist Securities raising its price target from $80 to $100. The acquisition adds two revenue-generating rare disease therapies and diversifies BioMarin's portfolio, though longer-term technical trends remain under pressure.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to merger and acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.

Amicus Therapeutics will participate in two healthcare investor conferences in November 2025, presenting at UBS Global Healthcare Conference and Jefferies Global Healthcare Conference, with live audio webcasts available.

Global Pompe disease treatment market is growing steadily, driven by enzyme replacement therapies and improved diagnostic technologies, with ongoing research into gene therapy and small molecule treatments promising more efficient solutions.

Amicus Therapeutics will present at two healthcare investor conferences in September 2025, including the Cantor Global Healthcare Conference and Morgan Stanley Global Healthcare Conference, with live audio webcasts available.

Pharmaceutical companies are advancing treatments for rare diseases, with Soligenix leading efforts in developing HyBryte, a promising therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting older adults.

Amicus Therapeutics reported Q2 2025 total revenue of $154.7M, up 18% at constant exchange rates, with strong performance from Galafold and Pombiliti + Opfolda. The company expects to reach GAAP profitability in H2 2025 and anticipates exceeding $1 billion in total revenue by 2028.